Opendata, web and dolomites

GOLIATH SIGNED

Beating Goliath: Generation Of NoveL, Integrated and Internationally Harmonised Approaches for Testing Metabolism Disrupting Compounds

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GOLIATH project word cloud

Explore the words cloud of the GOLIATH project. It provides you a very rough idea of what is the project "GOLIATH" about.

disruption    metabolic    exposures    life    natural    silico    comprised    screening    epidemiology    world    outcomes    collectively    goliathan    entire    regulation    lack    worldwide    link    spectrum    validation    health    regulatory    pancreatic    endocrinology    sc1    urgent    human    translating    acceptance    optimise    disrupt    goliath    metabolism    anthropogenic    internationally    span    oecd    mdcs    liver    fatty    proportions    chemical    first    guidelines    2018    disrupting    technologies    iata    pivotal    toxicology    myocytes    adverse    vivo    cellular    induce    experts    action    reduce    edcs    focussing    ongoing    international    strategy    biology    generate    validated    outcome    chemicals    reached    adipocytes    incorporating    molecular    ready    aop    diabetes    bhc    disorders    vitro    cells    27    harmonised    toxicity    assays    humans    obesity    predictive    throughput    omics    mode    endocrine    hepatocytes    ultimately   

Project "GOLIATH" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITEIT UTRECHT 

Organization address
address: HEIDELBERGLAAN 8
city: UTRECHT
postcode: 3584 CS
website: www.uu.nl

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 6˙761˙833 €
 EC max contribution 6˙761˙833 € (100%)
 Programme 1. H2020-EU.3.1.1. (Understanding health, wellbeing and disease)
 Code Call H2020-SC1-2018-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2019
 Duration (year-month-day) from 2019-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITEIT UTRECHT NL (UTRECHT) coordinator 1˙268˙269.00
2    INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE FR (PARIS) participant 1˙077˙695.00
3    INSTITUT NATIONAL DE RECHERCHE POUR L'AGRICULTURE, L'ALIMENTATION ET L'ENVIRONNEMENT FR (PARIS CEDEX 07) participant 798˙786.00
4    UNIVERSIDAD MIGUEL HERNANDEZ DE ELCHE ES (ELCHE) participant 672˙862.00
5    Department of Health UK (Leeds) participant 459˙104.00
6    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 402˙500.00
7    THE REGENTS OF THE UNIVERSITY OF CALIFORNIA US (OAKLAND CA) participant 339˙596.00
8    LINKOPINGS UNIVERSITET SE (LINKOPING) participant 338˙287.00
9    UMEA UNIVERSITET SE (UMEA) participant 303˙750.00
10    BRUNEL UNIVERSITY LONDON UK (UXBRIDGE) participant 261˙946.00
11    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 248˙525.00
12    BIOPREDIC INTERNATIONAL SARL FR (SAINT GREGOIRE) participant 243˙750.00
13    VLAAMSE INSTELLING VOOR TECHNOLOGISCH ONDERZOEK N.V. BE (MOL) participant 137˙510.00
14    AGENCE NATIONALE DE LA SECURITE SANITAIRE DE L ALIMENTATION DE L ENVIRONNEMENT ET DU TRAVAIL FR (MAISONS ALFORT) participant 134˙250.00
15    HOFFMANN SEBASTIAN DE (PADERBORN) participant 75˙000.00

Map

 Project objective

GOLIATH addresses the work programme topic ‘SC1-BHC-27-2018: New testing and screening methods to identify endocrine disrupting chemicals (EDCs)’ by focussing on one of the most urgent regulatory needs, namely the lack of methods for testing EDCs that disrupt metabolism – chemicals collectively referred to as ‘metabolism disrupting chemicals’ (MDCs). MDCs are natural and anthropogenic chemicals that have the ability to promote metabolic changes that can ultimately result in obesity, diabetes and/or fatty liver in humans. GOLIATH will generate the world’s first integrated approach to testing and assessment (IATA) specifically tailored to MDCs. With a focus on the main cellular targets of metabolic disruption – hepatocytes, pancreatic endocrine cells, myocytes and adipocytes - GOLIATH will develop new methods and optimise existing methods that span the entire adverse outcome pathway (AOP) spectrum, using in silico predictive modelling and high throughput screening, (pre-)validated ready-to-use in vitro assays and optimised in vivo toxicity testing guidelines. GOLIATH will provide key information on the endocrine mode of action by which MDCs disrupt metabolic pathways and induce adverse effects on human health by incorporating multi-omics technologies, and translating results from in vitro and in vivo assays to adverse metabolic health outcomes in humans at real life exposures. Given the importance of international acceptance of the developed test methods for regulatory use, GOLIATH will link with ongoing initiatives of the OECD for test method (pre-)validation, IATA and AOP development. With a consortium comprised of world-leading experts in endocrinology, molecular biology, toxicology, epidemiology, test method development, validation and chemical regulation, GOLIATH will be pivotal in the development of an internationally harmonised strategy for testing MDCs, and help to reduce the worldwide rise in metabolic disorders that have reached ‘Goliathan’ proportions.

 Deliverables

List of deliverables.
Detailed review paper on state of the art on MDCs Documents, reports 2020-03-06 13:48:50
Website open to the general public Websites, patent fillings, videos etc. 2020-02-25 14:36:32

Take a look to the deliverables list in detail:  detailed list of GOLIATH deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Melanie Schneider, Jean-Luc Pons, William Bourguet, Gilles Labesse
Towards accurate high-throughput ligand affinity prediction by exploiting structural ensembles, docking metrics and ligand similarity
published pages: 160-168, ISSN: 1367-4803, DOI: 10.1093/bioinformatics/btz538
Bioinformatics 36/1 2020-02-25
2019 Melanie Schneider, Jean-Luc Pons, Gilles Labesse, William Bourguet
In Silico Predictions of Endocrine Disruptors Properties
published pages: 2709-2716, ISSN: 1945-7170, DOI: 10.1210/en.2019-00382
Endocrinology 160/11 2020-02-25

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GOLIATH" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GOLIATH" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.1.)

DECISION (2020)

DECOMPENSATED CIRRHOSIS: IDENTIFICATION OF NEW COMBINATORIAL THERAPIES BASED ON SYSTEMS APPROACHES

Read More  

BIND (2020)

Brain Involvement iN Dystrophinopathies

Read More  

CANDY (2020)

Comorbid Analysis of Neurodevelopmental Disorders and Epilepsy

Read More